INV21

INV21 is an inactivated whole-virus vaccine candidate developed for the prevention of hand, foot, and mouth disease (HFMD) caused by Enterovirus 71 (EV71). Originally developed by Inviragen in collaboration with the Duke-NUS Graduate Medical School, the program was acquired by Takeda Pharmaceutical Company in 2015. The vaccine consists of purified EV71 virus that has been inactivated with formalin and adsorbed to an aluminum hydroxide adjuvant. It was designed to address the significant burden of EV71-associated HFMD in the Asia-Pacific region, where the virus is a leading cause of neurological complications and fatalities in young children. INV21 successfully completed a Phase 1 clinical trial in healthy adults, demonstrating safety and the induction of neutralizing antibodies. However, the program was subsequently discontinued as Takeda focused its vaccine pipeline on other priorities, such as its dengue and chikungunya candidates.

Other names

EV71 vaccineEV-71 vaccineEV 71 vaccineEnterovirus 71 vaccineEnterovirus71 vaccineEnterovirus-71 vaccineInviragen HFMD vaccine